NR 666.510(3)(d)5.b. b. Produce uncontrolled toxic mists, fumes, dusts, or gases in sufficient quantities to threaten human health.

NR 666.510(3)(d)5.c. c. Produce uncontrolled flammable fumes or gases in sufficient quantities to pose a risk of fire or explosions.

NR 666.510(3)(d)5.d. d. Damage the structural integrity of the container of hazardous waste pharmaceuticals.

NR 666.510(3)(d)5.e. e. Through other like means threaten human health or the environment.

NR 666.510(3)(d)6. 6. Accumulate evaluated hazardous waste pharmaceuticals that are prohibited from being combusted because of the dilution prohibition under s. NR 668.03 (3), for example arsenic trioxide (P012), in separate containers from other evaluated hazardous waste pharmaceuticals at the reverse distributor.

NR 666.510(3)(e) (e) Hazardous waste numbers. Prior to shipping evaluated hazardous waste pharmaceuticals off-site, all containers shall be marked with the applicable hazardous waste numbers, or hazardous waste codes. A nationally recognized electronic system, such as bar coding or radio frequency identification, may be used to identify the EPA hazardous waste numbers.

NR 666.510(3)(f) (f) Shipments. A reverse distributor shall ship evaluated hazardous waste pharmaceuticals that are destined for a permitted or interim status treatment, storage, or disposal facility in accordance with the applicable shipping standards specified in s. NR 666.508 (1) or (2).

NR 666.510(3)(g) (g) Procedures for a reverse distributor for managing rejected shipments. A reverse distributor that sends a shipment of evaluated hazardous waste pharmaceuticals to a designated facility with the understanding that the designated facility can accept and manage the waste, and later receives that shipment back as a rejected load in accordance with the manifest discrepancy provisions under s. NR 664.0072 or 665.0072, may accumulate the returned evaluated hazardous waste pharmaceuticals on-site for up to an additional 90 calendar days in the on-site accumulation area provided the rejected or returned shipment is managed in accordance with sub. (1) and this subsection. Upon receipt of the returned shipment, the reverse distributor shall do all of the following:

NR 666.510(3)(g)1. 1. Sign one of the following:

NR 666.510(3)(g)1.a. a. Item 18c of the original manifest, if the original manifest was used for the returned shipment.

NR 666.510(3)(g)1.b. b. Item 20 of the new manifest, if a new manifest was used for the returned shipment.

NR 666.510(3)(g)2. 2. Provide the transporter a copy of the manifest.

NR 666.510(3)(g)3. 3. Within 30 calendar days of receipt of the rejected shipment of the evaluated hazardous waste pharmaceuticals, send a copy of the manifest to the designated facility that returned the shipment to the reverse distributor.

NR 666.510(3)(g)4. 4. Within 90 calendar days of receipt of the rejected shipment, transport or offer for transport the returned shipment of evaluated hazardous waste pharmaceuticals in accordance with the applicable shipping standards under s. NR 666.508 (1) or (2).

NR 666.510(3)(h) (h) Land disposal restrictions. Evaluated hazardous waste pharmaceuticals are subject to the land disposal restrictions under ch. NR 668. A reverse distributor that accepts potentially creditable hazardous waste pharmaceuticals from off-site shall comply with the land disposal restrictions in accordance with s. NR 668.07 (1) requirements.

NR 666.510(3)(i) (i) Reporting by a reverse distributor for evaluated hazardous waste pharmaceuticals.

NR 666.510(3)(i)1. 1. ‘Annual reporting by a reverse distributor.’ A reverse distributor that ships evaluated hazardous waste pharmaceuticals off-site shall prepare and submit a single copy of an annual report to the department by March 1 of each year in accordance with s. NR 662.041.

NR 666.510(3)(i)2. 2. ‘Exception reporting by a reverse distributor for a missing copy of the manifest - shipments from a reverse distributor to a designated facility.’

NR 666.510(3)(i)2.a. a. A reverse distributor who does not receive a copy of the manifest with the signature of the owner or operator of the designated facility within 35 calendar days of the date the evaluated hazardous waste pharmaceuticals were accepted by the initial transporter, shall contact the transporter or the owner or operator of the designated facility to determine the status of the evaluated hazardous waste pharmaceuticals.

NR 666.510(3)(i)2.b. b. A reverse distributor shall submit an exception report to the department if it has not received a copy of the manifest with the signature of the owner or operator of the designated facility within 45 calendar days of the date the evaluated hazardous waste pharmaceutical was accepted by the initial transporter. The exception report shall include all of the following:

1) A legible copy of the manifest for which the reverse distributor does not have confirmation of delivery.

2) A cover letter signed by the reverse distributor, or its authorized representative, explaining the efforts taken to locate the evaluated hazardous waste pharmaceuticals and the results of those efforts.

NR 666.510(3)(i)3. 3. ‘Exception reporting by a reverse distributor for a missing copy of the manifest - shipments rejected by the designated facility and shipped to an alternate facility.’

NR 666.510(3)(i)3.a. a. A reverse distributor that does not receive a copy of the manifest with the signature of the owner or operator of the alternate facility within 35 calendar days of the date the evaluated hazardous waste pharmaceuticals were accepted by the initial transporter shall contact the transporter or the owner or operator of the alternate facility to determine the status of the hazardous waste. The 35-day time frame begins the date the evaluated hazardous waste pharmaceuticals are accepted by the transporter forwarding the hazardous waste shipment from the designated facility to the alternate facility.

NR 666.510(3)(i)3.b. b. A reverse distributor shall submit an exception report to the department if it has not received a copy of the manifest with the signature of the owner or operator of the alternate facility within 45 calendar days of the date the evaluated hazardous waste pharmaceuticals were accepted by the initial transporter. The 45-day timeframe begins the date the evaluated hazardous waste pharmaceuticals are accepted by the transporter forwarding the hazardous waste pharmaceutical shipment from the designated facility to the alternate facility. The exception report shall include all of the following:

1) A legible copy of the manifest for which the generator does not have confirmation of delivery.

2) A cover letter signed by the reverse distributor, or its authorized representative, explaining the efforts taken to locate the evaluated hazardous waste pharmaceuticals and the results of those efforts.

NR 666.510(3)(j) (j) Recordkeeping by a reverse distributor for evaluated hazardous waste pharmaceuticals.

NR 666.510(3)(j)1. 1. A reverse distributor shall keep a log, written or electronic, of the inspections of the on-site accumulation area, as required under par. (b). This log shall be retained as a record for at least 3 years from the date of the inspection.